Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vaccine (COVID-19 Vaccine Moderna®; Moderna) and ChAdOx1 nCoV-19 (COVID-1 Instituut voor Tropische Geneeskunde
Trial design: A prospective, post marketing, randomized, partially single blind, multicenter, interventional study